CARLSBAD, Calif., – September 22, 2010 – Life Technologies Corporation today announced the launch of two new assay kits, the Applied Biosystems NA-XTD™ and the NA-Fluor™ Influenza Neuraminidase Assay Kits designed to detect and quantitate influenza viral resistance to neuraminidase inhibitors.  These new kits, including the first-generation NA-Star® kit are the only kits currently available for quantifying influenza virus sensitivity to neuraminidase inhibitors.

Neuraminidase inhibitors are the drugs of choice in treatment of influenza infection. However, the efficacy of these drugs may be limited by the development of resistance by some strains of the influenza virus. Testing of flu virus isolates for resistance allows researchers to better understand the epidemiology of flu infections, including seasonal, pandemic and avian virus. The importance of drug resistance surveillance is indicated by the U.S. Centers for Disease Control report that only 19% of the seasonal H1N1 flu virus isolates tested during the 2007-2008 season were resistant to the neuraminidase inhibitor oseltamivir.  By February of 2009, the rate of resistance had risen to 98%, making oseltamivir ineffective for the treatment of seasonal flu infection.

The new kits facilitate easy screening of inhibitors of neuraminidase activity in influenza virus that can be applied to cell-based viral assays, screening and characterization of new NA inhibitors.  The kits are available in chemiluminescent or fluorescent read-outs.  The NA-XTD Influenza Neuraminidase Assay kit provides a stable chemiluminescent read-out enabling the use of simple luminometers without the need of reagent injection and the NA-Fluor Influenza Neuraminidase Assay Kit provides a fluorescent read-out based on the MUNANA substrate and the protocol and reagents are optimized to give data comparable to established published protocols.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website:

Life Technologies Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Media Contact
Lauren Lum
Life Technologies